Analysts Set Avalo Therapeutics, Inc. (NASDAQ:AVTX) Price Target at $45.80

Avalo Therapeutics, Inc. (NASDAQ:AVTX) has been given an average rating of “Moderate Buy” by the fourteen ratings firms that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating and thirteen have assigned a buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $45.80.

A number of analysts recently commented on AVTX shares. HC Wainwright dropped their price target on Avalo Therapeutics from $40.00 to $35.00 and set a “buy” rating on the stock in a report on Thursday, May 14th. Wolfe Research assumed coverage on shares of Avalo Therapeutics in a report on Thursday, April 9th. They set an “outperform” rating and a $48.00 price objective for the company. Wall Street Zen raised shares of Avalo Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Sunday, March 29th. Piper Sandler restated an “overweight” rating and set a $60.00 price target (up from $48.00) on shares of Avalo Therapeutics in a research note on Monday, May 11th. Finally, Citizens Jmp lowered their price target on shares of Avalo Therapeutics from $62.00 to $55.00 and set a “market outperform” rating on the stock in a report on Thursday, May 14th.

Insider Activity

In other news, CFO Christopher Ryan Sullivan sold 8,458 shares of Avalo Therapeutics stock in a transaction dated Wednesday, April 29th. The stock was sold at an average price of $13.09, for a total transaction of $110,715.22. Following the completion of the sale, the chief financial officer owned 8,880 shares in the company, valued at approximately $116,239.20. This trade represents a 48.78% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Paul Varki sold 75,063 shares of the stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $20.17, for a total value of $1,514,020.71. Following the completion of the transaction, the insider directly owned 3,634 shares in the company, valued at approximately $73,297.78. This represents a 95.38% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 93,428 shares of company stock worth $1,762,722. 4.46% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Avalo Therapeutics

Large investors have recently made changes to their positions in the business. PFS Partners LLC raised its holdings in shares of Avalo Therapeutics by 100.0% during the fourth quarter. PFS Partners LLC now owns 2,000 shares of the company’s stock valued at $36,000 after acquiring an additional 1,000 shares in the last quarter. Boothbay Fund Management LLC bought a new position in shares of Avalo Therapeutics during the second quarter valued at $56,000. Dimensional Fund Advisors LP purchased a new stake in Avalo Therapeutics during the 3rd quarter valued at $143,000. AlphaCentric Advisors LLC purchased a new position in shares of Avalo Therapeutics in the first quarter worth $174,000. Finally, Jump Financial LLC bought a new position in shares of Avalo Therapeutics during the fourth quarter valued at $238,000. 87.06% of the stock is currently owned by institutional investors.

Avalo Therapeutics Stock Performance

Shares of AVTX stock opened at $19.37 on Monday. Avalo Therapeutics has a 52-week low of $5.50 and a 52-week high of $24.27. The company has a 50-day simple moving average of $16.85 and a two-hundred day simple moving average of $16.10. The company has a market capitalization of $1.02 billion, a price-to-earnings ratio of -3.55 and a beta of 0.78.

Avalo Therapeutics (NASDAQ:AVTX) last posted its earnings results on Wednesday, May 13th. The company reported ($0.98) EPS for the quarter, topping the consensus estimate of ($1.00) by $0.02. On average, sell-side analysts forecast that Avalo Therapeutics will post -2.58 EPS for the current fiscal year.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.